[{"id":"1ab27b74-e0f4-4cec-8b70-3ecfc4fb824b","acronym":"Ven-BUCY","url":"https://clinicaltrials.gov/study/NCT07183878","created_at":"2025-09-27T08:46:54.624Z","updated_at":"2025-09-27T08:46:54.624Z","phase":"","brief_title":"Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)","source_id_and_acronym":"NCT07183878 - Ven-BUCY","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 08/20/2025","start_date":" 08/20/2025","primary_txt":" Primary completion: 08/20/2027","primary_completion_date":" 08/20/2027","study_txt":" Completion: 08/20/2028","study_completion_date":" 08/20/2028","last_update_posted":"2025-09-19"},{"id":"17c029cc-5449-4ba9-99f6-13ebaefd3227","acronym":"EVOLVE 1","url":"https://clinicaltrials.gov/study/NCT07075016","created_at":"2025-07-26T13:34:40.222Z","updated_at":"2025-07-26T13:34:40.222Z","phase":"Phase 3","brief_title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","source_id_and_acronym":"NCT07075016 - EVOLVE 1","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 227","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-07-20"},{"id":"1788e76b-7d7b-4891-bdd0-dfbb58176132","acronym":"","url":"https://clinicaltrials.gov/study/NCT07046078","created_at":"2025-07-05T13:57:24.531Z","updated_at":"2025-07-05T13:57:24.531Z","phase":"Phase 2","brief_title":"Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer","source_id_and_acronym":"NCT07046078","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • fludarabine IV • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2025-07-02"},{"id":"2d611a75-574e-482e-91b3-3bf96d4e7ace","acronym":"CATCHAML","url":"https://clinicaltrials.gov/study/NCT04318678","created_at":"2021-01-18T20:55:40.221Z","updated_at":"2025-02-25T12:27:32.189Z","phase":"Phase 1","brief_title":"CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","source_id_and_acronym":"NCT04318678 - CATCHAML","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD123 • IL3RA","pipe":"","alterations":" ","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • mesna • CD123-CAR T cell therapy • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-24"},{"id":"8071c405-9b54-4ff6-82e5-09e8fad7fb2c","acronym":"T-LGLL","url":"https://clinicaltrials.gov/study/NCT05141682","created_at":"2021-12-02T18:54:30.785Z","updated_at":"2025-02-25T12:38:03.521Z","phase":"Phase 1/2","brief_title":"Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia","source_id_and_acronym":"NCT05141682 - T-LGLL","lead_sponsor":"Jonathan Brammer","biomarkers":" CD8","pipe":" | ","alterations":" STAT3 mutation","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STAT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Onureg (azacitidine oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/29/2022","start_date":" 06/29/2022","primary_txt":" Primary completion: 08/15/2024","primary_completion_date":" 08/15/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"ef9f9bd0-273f-42be-ab92-31c003721bbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01861106","created_at":"2021-01-18T08:19:16.098Z","updated_at":"2025-02-25T12:26:02.331Z","phase":"Phase 2","brief_title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","source_id_and_acronym":"NCT01861106","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GATA2","pipe":" | ","alterations":" GATA2 mutation","tags":["GATA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GATA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 07/24/2013","start_date":" 07/24/2013","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-24"},{"id":"23ac8e6c-a9b5-4a23-995c-206f44787ba3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02890329","created_at":"2021-01-18T14:11:09.765Z","updated_at":"2025-02-25T13:48:17.623Z","phase":"Phase 1","brief_title":"Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","source_id_and_acronym":"NCT02890329","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" High ALC","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e High ALC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • azacitidine • decitabine • CS1002 (ipilimumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/05/2017","start_date":" 09/05/2017","primary_txt":" Primary completion: 10/24/2022","primary_completion_date":" 10/24/2022","study_txt":" Completion: 08/19/2025","study_completion_date":" 08/19/2025","last_update_posted":"2025-02-21"},{"id":"30691860-7f81-43a1-b334-a75b53b70fce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04959175","created_at":"2021-07-13T12:53:21.217Z","updated_at":"2025-02-25T13:40:32.157Z","phase":"Phase 1/2","brief_title":"Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT04959175","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • IGH","pipe":"","alterations":" ","tags":["EGFR • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 09/23/2021","start_date":" 09/23/2021","primary_txt":" Primary completion: 04/27/2027","primary_completion_date":" 04/27/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-21"},{"id":"7db8cbc0-f928-4935-a5eb-7dd8dd21f64b","acronym":"EA2192","url":"https://clinicaltrials.gov/study/NCT04858334","created_at":"2021-04-26T13:52:59.130Z","updated_at":"2025-02-25T13:40:27.622Z","phase":"Phase 2","brief_title":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation","source_id_and_acronym":"NCT04858334 - EA2192","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" PALB2 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-21"},{"id":"9dace7a4-0aa6-4f4b-ad55-e52edc08eadf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04251078","created_at":"2021-01-18T20:39:29.313Z","updated_at":"2025-02-25T13:40:03.793Z","phase":"","brief_title":"Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples","source_id_and_acronym":"NCT04251078","lead_sponsor":"Josep Carreras Leukaemia Research Institute","biomarkers":" BRAF • SF3B1 • GATA1","pipe":"","alterations":" ","tags":["BRAF • SF3B1 • GATA1"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-21"},{"id":"b8897926-0522-4fee-9673-a3eb75b62670","acronym":"","url":"https://clinicaltrials.gov/study/NCT03173937","created_at":"2021-01-18T15:38:57.471Z","updated_at":"2025-02-25T13:39:29.284Z","phase":"Phase 1/2","brief_title":"Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome","source_id_and_acronym":"NCT03173937","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD34 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["CD34 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Omisirge (omidubicel)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 04/28/2025","primary_completion_date":" 04/28/2025","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2025-02-21"},{"id":"611d069e-ba56-4015-ba56-94bebd608133","acronym":"","url":"https://clinicaltrials.gov/study/NCT03839446","created_at":"2021-01-18T18:57:17.044Z","updated_at":"2025-02-25T13:52:47.649Z","phase":"Phase 2","brief_title":"Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy","source_id_and_acronym":"NCT03839446","lead_sponsor":"Robert Redner, MD","biomarkers":" CD33","pipe":" | ","alterations":" CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • Mylotarg (gemtuzumab ozogamicin) • mitoxantrone"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/28/2019","start_date":" 02/28/2019","primary_txt":" Primary completion: 02/02/2023","primary_completion_date":" 02/02/2023","study_txt":" Completion: 12/22/2024","study_completion_date":" 12/22/2024","last_update_posted":"2025-02-20"},{"id":"a2748e44-3f76-4ef4-9c24-1b7476039a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554393","created_at":"2022-09-26T14:56:10.693Z","updated_at":"2025-02-25T13:49:33.606Z","phase":"Phase 2","brief_title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","source_id_and_acronym":"NCT05554393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation","tags":["TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 09/13/2024","start_date":" 09/13/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"afc34dd5-440d-4768-b2d3-1f68bbdafbb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05470491","created_at":"2022-07-22T11:56:13.684Z","updated_at":"2025-02-25T13:54:33.177Z","phase":"Phase 1/2","brief_title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","source_id_and_acronym":"NCT05470491","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • Selzentry (maraviroc) • plerixafor"],"overall_status":"Recruiting","enrollment":" Enrollment 265","initiation":"Initiation: 01/26/2023","start_date":" 01/26/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2025-02-20"},{"id":"b813594c-e262-462c-9ebd-af975b8871b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04375631","created_at":"2021-01-18T21:08:17.296Z","updated_at":"2025-02-25T13:53:16.560Z","phase":"Phase 1","brief_title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT04375631","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/03/2020","start_date":" 12/03/2020","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 03/17/2027","study_completion_date":" 03/17/2027","last_update_posted":"2025-02-20"},{"id":"1858e4d9-b3bc-4f84-941b-cd90075ac7b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708054","created_at":"2021-01-19T20:51:54.886Z","updated_at":"2025-02-25T14:08:06.998Z","phase":"Phase 2","brief_title":"Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS","source_id_and_acronym":"NCT04708054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation","tags":["KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-18"},{"id":"e6419ea6-12ef-460f-8597-b07958498262","acronym":"IMMUNOMEK","url":"https://clinicaltrials.gov/study/NCT05937906","created_at":"2023-07-10T13:08:51.069Z","updated_at":"2025-02-25T14:09:51.533Z","phase":"Phase 1/2","brief_title":"Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 \u003c 50 %.","source_id_and_acronym":"NCT05937906 - IMMUNOMEK","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Gomekli (mirdametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/30/2024","start_date":" 07/30/2024","primary_txt":" Primary completion: 05/25/2028","primary_completion_date":" 05/25/2028","study_txt":" Completion: 05/25/2028","study_completion_date":" 05/25/2028","last_update_posted":"2025-02-18"},{"id":"0841b3a2-d056-4bdc-8db6-285dc71005a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02506933","created_at":"2021-01-18T12:06:04.560Z","updated_at":"2025-02-25T14:06:51.914Z","phase":"Phase 2","brief_title":"Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant","source_id_and_acronym":"NCT02506933","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Triplex (CMV-MVA vaccine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 11/05/2015","start_date":" 11/05/2015","primary_txt":" Primary completion: 01/25/2018","primary_completion_date":" 01/25/2018","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-17"},{"id":"ae37ad26-112d-406e-b4ec-b9bd80c911c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05292664","created_at":"2022-03-23T13:53:35.750Z","updated_at":"2025-02-25T14:08:44.222Z","phase":"Phase 1","brief_title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","source_id_and_acronym":"NCT05292664","lead_sponsor":"Andrew E. Place, MD","biomarkers":" FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1","pipe":" | ","alterations":" KMT2A rearrangement • ABL1 fusion","tags":["FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 03/29/2023","start_date":" 03/29/2023","primary_txt":" Primary completion: 07/02/2026","primary_completion_date":" 07/02/2026","study_txt":" Completion: 07/02/2028","study_completion_date":" 07/02/2028","last_update_posted":"2025-02-17"},{"id":"5c523880-f8a6-448f-8403-e3010aefe575","acronym":"","url":"https://clinicaltrials.gov/study/NCT03772925","created_at":"2021-01-18T18:39:51.839Z","updated_at":"2025-02-25T14:40:05.004Z","phase":"Phase 1","brief_title":"Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT03772925","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • CD4","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation","tags":["BCL2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pevonedistat (MLN4924) • Beleodaq (belinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/20/2019","start_date":" 06/20/2019","primary_txt":" Primary completion: 06/16/2025","primary_completion_date":" 06/16/2025","study_txt":" Completion: 06/16/2025","study_completion_date":" 06/16/2025","last_update_posted":"2025-02-14"},{"id":"002fe85e-b3d8-4f4c-9679-0e7ceacd8f48","acronym":"MCC-20963","url":"https://clinicaltrials.gov/study/NCT05177211","created_at":"2022-01-04T13:53:44.017Z","updated_at":"2025-02-25T14:16:34.238Z","phase":"Phase 2","brief_title":"Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)","source_id_and_acronym":"NCT05177211 - MCC-20963","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inrebic (fedratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-13"},{"id":"460f1e61-72a2-48bb-a37c-e804016f6240","acronym":"NCI-2021-06095","url":"https://clinicaltrials.gov/study/NCT05010122","created_at":"2021-08-18T15:53:42.501Z","updated_at":"2025-02-25T15:12:15.219Z","phase":"Phase 1/2","brief_title":"ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT05010122 - NCI-2021-06095","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/08/2021","start_date":" 07/08/2021","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-13"},{"id":"52201742-0575-4575-a34b-9248823aad77","acronym":"APAL2020SC","url":"https://clinicaltrials.gov/study/NCT04726241","created_at":"2021-01-27T13:53:55.563Z","updated_at":"2025-02-25T15:11:53.004Z","phase":"Phase 1/2","brief_title":"The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia \u0026 Lymphoma Society and Children's Oncology Group Study","source_id_and_acronym":"NCT04726241 - APAL2020SC","lead_sponsor":"LLS PedAL Initiative, LLC","biomarkers":" KMT2A","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"],"overall_status":"Recruiting","enrollment":" Enrollment 960","initiation":"Initiation: 04/18/2022","start_date":" 04/18/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-13"},{"id":"f18181fc-ba3a-410b-9369-091830924976","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457556","created_at":"2022-09-07T16:55:34.255Z","updated_at":"2025-02-25T15:12:56.234Z","phase":"Phase 3","brief_title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT05457556","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • methotrexate • melphalan • Truxima (rituximab-abbs) • fludarabine IV • thiotepa • busulfan • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 435","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-13"}]